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insights on model constructs, key data elements/assumptions, and recent mod-
eling advances. Results: Thirty-three HTAs comprising 60 CUAs were considered 
relevant and investigated further. Albeit individual sampling models and discrete 
event simulations have some advantages over Markov models, these three tech-
niques may provide similar cost-effectiveness estimates and were all deemed 
appropriate for HTA submissions. At least ten different structural components 
were identified for which data sources and/or assumptions have evolved over time, 
several of which have a major bearing on model outcomes. The characteristics of 
patients entering the model (e.g. disease severity and prior treatments), assump-
tions about long-term disease progression whilst on treatment and the rebound 
effect upon treatment discontinuation, and mapping of Health Assessment 
Questionnaire and/or pain scores to Quality of Life utility values were repeatedly 
mentioned as key elements affecting the results. ConClusions: A wide variety 
of economic models for the evaluation of bDMARDS in RA have been developed 
and are continuously being refined. Despite recent initiatives to reach consensus 
on how RA models should be designed, substantial differences in the data sources 
and assumptions that are used still remain. This limits the comparability across 
and also generalizability of the various results obtained by using these models 
and poses problems to all stakeholders involved in HTAs.
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objeCtives: One of the major critiques with submitted manufacturer’s cost-
effectiveness models is surrounding the structural uncertainty. However, methods 
dealing with structural uncertainties are not well-developed, even though these 
might have a significant impact on model results. This study investigates the 
impact of structural changes in a National Institute for Health and Care Excellence 
(NICE) single technology appraisal cost-effectiveness model of Erlotinib versus 
Best Supportive Care as a maintenance therapy for patients with non-small cell 
lung cancer. The manufacturer’s model submission was criticised for having a 
“Markov” model not governed by transition probabilities. It considered an inde-
pendent projective survival functions for progression-free survival and overall 
survival, which allowed a negative post-progression survival (PPS) estimate to 
appear in later cycle. Methods: Using published summary survival data, this 
study adopted three approaches, covering both fixed- and time-varying, to esti-
mate health state transition probabilities that are used in a restructured Markov 
model. Results: Unlike for placebo, the parametric approach estimates post-
progression probabilities and probabilities of death for Erlotinib differently than 
fixed-transition approaches. The best fitting curves are achieved for both PPS 
and probability of death across the time for which data were available, but the 
curves start diverging towards the end of this period. The alternative (Markov) 
model which extrapolates the curves forward in time suggests that this differ-
ence between a time-varying and fixed-transition becomes even greater. The 
alternative models produce an Incremental Cost-Effectiveness Ratio (ICER) 
of £54k -£66k per quality adjusted life year (QALY) gain, which is comparable 
to an ICER presented in the MS (£55k/QALY gain). ConClusions: The results 
from restructured alternative models do not suggest different cost-effectiveness 
results to those reported in the manufacturer submission; however, in terms of 
magnitude they vary. This variation in cost-effectiveness results produced by 
restructured models might be crucial for interventions falling near a threshold 
value.
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objeCtives: Autosomal dominant polycystic kidney disease (ADPKD) is a genetic 
disorder characterised by enlarged kidneys and declining renal function. ADPKD 
progression rates are heterogeneous, influenced by age, gender, renal size and 
genotype. Disease models often utilise progression rates derived from published 
studies. This study aimed to compare ADPKD progression, in terms of changes in 
total kidney volume (TKV) and renal function, modelled from summary versus 
patient-level data (PLD), and assess the consistency of predictions with trial obser-
vations. Methods: Regression equations were derived from the TEMPO 3:4 trial 
placebo arm (natural history) to predict annual changes in TKV and estimated glo-
merular filtration rate (eGFR). Candidate covariates included age, gender, ethnicity, 
region/country, TKV and eGFR. Predictions were compared using the PLD regres-
sion equations or linear interpolation of summary rates of change in four patient 
categories. Finally, the model was initiated with published baseline patient pro-
files representing early and late disease from the HALT-PKD trials, and predicted 
progression compared to trial observations. Results: For patients initiated with 
the average TEMPO 3:4 placebo profile, predicted eGFR trajectories based on PLD 
or summary data were similar (average decline: -5.3 and -5.1ml/min/1.73m2/year, 
respectively); however, TKV predictions deviated as TKV exceeded 2,500ml, with 
increasingly rapid growth predicted based on summary data. The model closely 
replicated ADPKD progression among patients with early disease; all predicted 
values within the 95% confidence interval of HALT-PKD observations. In patients 
with late disease, modelled baseline TKV of 1,000-1,500ml led to closest replication 
of eGFR observations (average decline: -3.2 to -4.4, versus -3.9ml/min/1.73m2/year 
during trial). ConClusions: Though predictions based on summary and PLD 
were consistent, the PLD regression equations produced more realistic results at 
extreme values. The availability of relevant PLD to describe the natural history of 
ADPKD progression provides a more robust foundation for disease and economic 
modelling than summary data alone.
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objeCtives: To address the practical and methodological issues associated with 
using low-quality evidence outcomes in health economic modelling. Methods: A 
cost-effectiveness model for disease-modifying drugs (DMDs) in multiple sclerosis 
(MS) in The Netherlands was used to assess how to deal with low-quality evidence 
in health economic modelling. The model adopted a 10-year time horizon and a 
societal perspective. A Markov model was constructed based on EDSS staging in 
MS, including relapse. The central focus was on disease progression — instead of 
relapse — which appeared to be the driver of the cost-effectiveness outcomes. The 
main data source was a recent Cochrane review estimating relative efficacy and 
acceptability of DMDs in relapse-remitting MS. Other data sources included addi-
tional published literature, clinical trials, and official price/tariff lists. Results: The 
analysis based on the Cochrane review data showed that interferon beta-1a-R (Rebif) 
is cost-effective over interferon beta-1a-A (Avonex) (dominant) and interferon beta-
1b (€ 27,654/QALY), but that interferon beta-1a-R is not cost-effective over glatiramer 
acetate. However, for disease progression, the level of evidence is considered very 
low (level 1) for all drugs, except interferon beta-1a-R (moderate - level 3), implying 
unreliable effectiveness outcomes which, consequently, can result in unreliable 
cost-effectiveness outcomes. Two reasonable alternative approaches may be to 
exclude very low evidence from the cost-effectiveness analysis or assume placebo 
efficacy. Alternative analyses, including placebo efficacy for disease progression for 
drugs of which the evidence is labelled very low by Cochrane (all except interferon 
beta-1a-R), strongly impacted outcomes: interferon beta-1a-R was cost-effective 
over interferon beta-1a-A (dominant), interferon beta-1b (€ 6,265), and glatiramer 
acetate (dominant). ConClusions: Inclusion of very low-quality evidence in health 
economic modelling may lead to unreliable cost-effectiveness conclusions. However, 
a gold standard is lacking for handling levels of clinical evidence in health economic 
models. One alternative, presented here, would be to assume placebo efficacy in 
such cases.
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objeCtives: To evaluate different statistical methodologies in a network meta-
analysis (NMA) comparing the effectiveness of interferon-beta (IFNβ ) therapies 
across several endpoints in relapsing-remitting multiple sclerosis (RRMS) to 
determine potential best practices. Methods: A systematic literature review 
(1996-2014) was conducted to identify randomised, controlled trials of FDA- and 
EMA-approved IFNβ DMDs in RRMS, including subcutaneous (SC) IFNβ -1a (44μ g or 
22μ g 3x/wk), SC pegIFNβ -1a (125μ g every 2wks), intramuscular (IM) IFNβ -1a (30μ g 
1x/wk), and SC IFNβ -1b (250μ g EOD). Data were extracted for patients relapse-free, 
patients without disability progression, and patients without new MRI activity 
at study end. A random-effects Bayesian model was utilised for the base case 
analysis, and sensitivity analyses investigated results using different analysis 
frameworks or effects distributions. Results: 644 articles were retrieved; 14 met 
inclusion criteria and reported evaluable data. The evidence networks had few 
connections between nodes, with a maximum of 10 connections for the proportion 
of “patients relapse-free” endpoint. In addition, there were few connections with 
multiple studies linking nodes, with a maximum of 50% (5/10) of connections hav-
ing more than one study on the relapse endpoint, and there were at most two stud-
ies linking any two nodes. Because of the small number of studies linking nodes, 
a random-effects Bayesian model with uninformative priors resulted in wide 
credible intervals, complicating interpretation of results; uncertainty decreased 
using a random-effects Bayesian model with an informative prior as well as with 
a fixed-effects Bayesian model. Estimates for the treatment effects were similar 
across all Bayesian approaches. Utilising a Frequentist approach resulted in similar 
estimates for treatment effects compared to the Bayesian analyses framework, 
although with slightly less uncertainty. ConClusions: While similar estimates 
for treatment effects were found across statistical methodologies, the combi-
nation of a Bayesian approach and a random-effects distribution with informa-
tive prior allowed for methodological robustness while yielding interpretable 
findings.
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objeCtives: Over the last decade, several biologic disease-modifying anti-
rheumatic drugs (bDMARDs) have become available providing additional treat-
ment options for rheumatoid arthritis (RA) patients. This study was conducted 
to identify and compare existing economic models used by health technology 
assessment (HTA) bodies to evaluate bDMARDs. Methods: The HTA Accelerator 
database and websites of HTA agencies (NICE, SMC, NCPE, ZIN, TLV, PBAC, CADTH, 
INESSS, MOHLTC, DECIT-CGATS and AHRQ) were screened to identify assess-
ments of bDMARDs published since 2005 that included a cost-utility analysis 
(CUA). In addition, a targeted literature review was performed to gain further 
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unlicensed comparator bevacizumab, the frequency and duration of treatment, and 
the extrapolation of visual acuity beyond short-term observed trial data. The trial 
evidence used ranged from 6 months to 3 years and included evidence for treatment 
in one eye only. Most TAs modelled one treated eye only, with crude adjustments 
applied to account for bilateral treatment. Only the most recent appraisal for afliber-
cept in central RVO modelled the visual acuity of both eyes. All other uncertainties 
were consistent throughout the identified TAs. ConClusions: The main uncer-
tainties are in which eye(s) patients are treated in practice and the extrapolation of 
outcomes beyond trial data. Modelling is limited by short-term clinical trial evidence 
that provides evidence for the treatment of one eye only.
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objeCtives: Standard approaches to evaluating the health economic benefit of avoid-
ing hypoglycaemia often attribute a per-event disutility (PED) with growing evidence 
of the diminishing marginal effects (DME) of hypoglycaemia on utility as frequency 
increases. This study compared PED to DME on predicted quality adjusted life expec-
tancy (QALE). Methods: This study used the CORE Diabetes Model (CDM) and pub-
lished audit data for patients with type 1 diabetes switching to insulin degludec (ID) 
from either insulin glargine or detemir (IGD). Mean (± SD) baseline profiles were age 
35.0 years (± 11.4); diabetes duration 18.2 years (± 7.5); HbA1c 9.4% (±0.8); weight 77.0 
kg (±10.7) and 3.9 hypoglycaemia (severe and non-severe) events per week (±0.9). 
Mean change in clinical variables was HbA1c -0.5% (±0.3); weight +0.8g (±1.6) and 
hypoglycaemia events/week -3.6 (±0.9). A baseline cohort was projected over a lifetime 
using the CDM using published PED disutility (-0.0052) and published DME disutility 
(0.0141*[number of events]^0.3393) with and without treatment effects applied to cal-
culate life expectancy (LE) and QALE associated with the pre and post-switch profiles. 
Results were discounted at 3.5%. Results: Overall discounted LE was 18.8 years and 
19.06 years for IGD and ID profiles respectively and discounted QALE (ignoring the 
impact of hypoglycaemia) was 12.13 and 12.4 for IGD and ID respectively. Discounted 
QALE was reduced by 1.85 (IGD) and 0.849 (ID) using the DME approach applied to 
hypoglycaemia rates of 3.9 and 0.4 events/week respectively. Using the PED approach 
discounted QALE was reduced by 22.96 (IGD) and 2.355 (ID). The PED approach resulted 
in a QALE prediction less than zero for IGD. ConClusions: Failure to adequately 
accommodate the relationship between hypoglycaemia frequency and utility within 
health economic evaluations may lead to misleading predictions and estimates of 
QALE that lack face validity; particularly when hypoglycaemia rates are high.
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objeCtives: End-stage renal disease (ESRD) poses a significant burden to both 
patients and healthcare systems. In patients with type 2 diabetes mellitus (T2DM) 
improvements in the management of cardiovascular (CV) risk factor management 
has reduced CV specific morbidity and mortality. Consequently, as patients live 
longer with T2DM it is likely that the incidence and prevalence of renal disease will 
increase over time. The objective of this study was to externally validate the renal 
specific disease progression rates used in the IMS CORE diabetes model (CDM) to 
the UKPDS 64 and UK clinical practice. Methods: A Markov state transition model 
was developed to predict the progression of renal disease populated with transition 
probabilities from the CDM (derived from US and Israeli published studies) and the 
UKPDS 64 nephropathy model. Time to ESRD and the cumulative percentage with 
ESRD at 10, 20 and 40 years, or lifetime, whichever occurred first, were compared and 
contrasted with published ESRD projections derived from UK clinical practice data 
(The Health Improvement Network [THIN]). Baseline patient characteristics were 
taken from published THIN data. Results: For T2DM subjects aged 51 with mean 
systolic blood pressure of 139mmHg and HbA1c of 8% the predicted time to ESRD 
was 23.39 and 24.02 years when using CDM and UKPDS 64 transition rates, respec-
tively. The cumulative incidence of ESRD at 10, 20 and 40 years was 2.21%, 10.04% and 
24.96% respectively with CDM and 3.29%, 9.88% and 26.73% with UKPDS 64. Predicted 
20-year cumulative risk of ESRD from THIN varied between 5-18% dependent upon 
cohort characteristics, consistent with output from both CDM (10.04%) and UKPDS 
(9.88%). ConClusions: This study provides evidence of the consistency between 
approaches to modelling renal disease employed by the CDM and reported from 
UKPDS; furthermore, both approaches provide estimates consistent with data from 
UK clinical practice.
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objeCtives: Remission, the spontaneous resolution of symptoms among patients, 
is one of the characteristics of chronic spontaneous (or idiopathic) urticaria (CSU/
CIU). Limited literature currently exists regarding remission rates among chronic urti-
caria (CU) or CSU/CIU patients and available estimates vary. Due to the requirements 
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objeCtives: To compare cost-effectiveness of delayed-release dimethyl-fuma-
rate (DMF; also known as gastro-resistant DMF) vs. pharmacological alternatives 
indicated for the first-line treatment of relapsing-remitting multiple sclero-
sis (RRMS), adopting the perspective of the Italian National Healthcare Service 
(NHS). Methods: A cost-effectiveness model was used to evaluate costs and 
outcomes of patients treated with DMF, vs. interferon beta-1a intramuscular (IFN 
beta-1a, IM), interferon beta-1a subcutaneous, at two different doses (IFN beta-1a, 
SC 22mcg and SC 44mcg), interferon beta-1b subcutaneous (IFN beta-1b, SC), glati-
ramer acetate subcutaneous (GA), and oral teriflunomide (TER). The Markov model 
used for the analysis evaluated the effects of disability progression, relapses, and 
treatment-related adverse events, on direct healthcare costs and quality adjusted 
survival of RRMS patients, over a 50-year (lifetime) horizon. Comparative effec-
tiveness and safety data used in the model were derived from a mixed treatment 
comparison. All unit tariffs and costs were adapted to the Italian setting. Results: 
Lifetime direct healthcare costs associated with DMF were € 276,500 per patient, 
yielding to 19.50 life-years (LYs) and 6.55 quality-adjusted LYs (QALYs). The incre-
mental cost-effectiveness ratio (ICER) of DMF vs. the analyzed alternatives ranged 
between € 11,272 per QALY gained (DMF vs. IFN-beta 1b SC) to € 23,409 per QALY 
gained (DMF vs. TER). DMF was dominant vs. IFN-beta 1a SC 44mcg. Probabilistic 
sensitivity analysis conducted on both clinical and economic data showed that like-
lihood for DMF of being cost-effective, using a willingness-to-pay (WTP) threshold of 
€ 50,000 per QALY gained, was between 70.0% (DMF vs. TER), and 92.8% (DMF vs. IFN-
beta 1b, SC). ConClusions: At the current pricing and reimbursement conditions 
established by the Italian NHS, DMF represents a cost-effective option vs. first-line 
treatments indicated in RRMS. ICER associated with DMF is much lower than the 
€ 50,000 per QALY gained value, the cost-effectiveness of dialysis, commonly used 
in Italy as benchmark to issue positive funding recommendation.
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objeCtives: We demonstrate an approach to assess the impact of uncertainty in 
risk predictions on health-economic outcomes in risk-stratified prevention strate-
gies, illustrated for preventive statin treatment based on 10-year coronary heart 
disease (CHD) risk predicted by the Framingham risk score (FRS). Methods: We 
refitted the FRS to three random samples of increasing size (N= 2,500, N= 1,000, 
N= 500) from a population-based cohort. A Markov decision-analytic model was 
used to simulate cohorts with preventive statin treatment in high-risk (FRS≥ 20%) 
individuals (ATPIII guideline). This treatment threshold was incrementally lowered 
to T= 0.0% with 0.5% decrements. Using the cohort the distribution of individuals 
over the low (< 0.5T%), intermediate (0.5T%-T%), and high (≥ T%) risk category and 
corresponding observed CHD-risks were calculated. The Net Health Benefit (NHB) 
(willingness-to-pay of $50,000/QALY) was calculated and uncertainty in outcomes 
was assessed with probabilistic sensitivity analysis. The NHB for each 0.5% risk 
category was calculated to assess the impact of risk prediction uncertainty on asso-
ciated uncertainty in NHB. Results: Prediction model performance was fair in all 
samples (c-statistic: 0.70-0.75). Prediction uncertainty resulted in probabilities of 
incorrect treatment decisions of up to 0.4 (N= 2,500) and 0.5 (N= 500) for risk around 
T= 20.0%. The NHBs per risk category ranged from -0.031 for a predicted risk of 
[3.5%;4%] to 0.020 for [10.0%;10.5%] in men and from -0.067 at [0.0%;0.5%] to 0.045 
for [2.0%;2.5%] in women. The NHB was positive for predicted risks > 12.5% in men 
and > 11.5% in women. For individuals with predicted risks < 7.5% or > 20%, in 95% 
of PSA simulations the NHB was negative or positive, respectively. ConClusions: 
Risk-stratified prevention is increasingly recommended. While uncertainty in risk 
predictions may lead to incorrect treatment decisions, associated impact on long-
term health-economic outcomes is unknown. Assessing this impact can guide 
studies aiming to improve prediction models by focusing on individuals for which 
improvement may actually improve health-economic outcomes.
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objeCtives: To identify and summarise challenges to the economic model-
ling of macular oedema due to retinal vein occlusion (RVO) and diabetic macu-
lar oedema (DMO). Methods: National Institute for Health and Care Excellence 
(NICE) technology appraisals (TAs) for RVO and DMO published before 1 June 2015 
were reviewed to identify areas of uncertainty in submitted economic models. 
Evaluations were compared to assess whether, over time, these uncertainties have 
been addressed. Results: Three completed NICE TAs were identified for RVO and 
two for DMO. The main area of uncertainty identified related to whether patients 
would be treated in their better-seeing eye (BSE), worse-seeing eye (WSE) or both 
eyes (bilateral), and consequently how this should be modelled. This had implica-
tions for the appropriate application of utility estimates for patients treated in the 
BSE, WSE or bilaterally and for the classification of patients as blind. Blindness is 
associated with high costs and low quality of life, which were incorrectly accounted 
for in one-eye models. Other areas of uncertainty included the relevance of the 
